The CFSRE's NPS Discovery program has developed an extensive and multidisciplinary network of collaborators, working closely with the forensic science community, medical examiners and coroners, crime laboratories, toxicology laboratories, and public health and safety agencies. NPS Discovery was designed with analytical testing as its core value, focusing on both novel testing for NPS and overall comprehensive drug testing on toxicology samples, drug materials, and other samples of interest. NPS Discovery has developed a variety of methodology and workflows for novel, prospective, and retrospective identification of emerging drugs through the use of highly sensitive and sophisticated mass spectrometry assays. Through vast collaborations and innovate testing, NPS Discovery continually seeks to identify novel drugs on their first instance within the drug supply, monitor increases in drug-related harms and overdoses through nation-wide toxicology testing, and track the prevalence and positivity of individual drugs as they emerge and eventually wane among the increasingly diverse drug supply.
The CFSRE would like to acknowledge its collaborative NPS partners, including NMS Labs, medical examiner and coroner offices, the International Society for the Study of Emerging Drugs (ISSED), the Philadelphia Department of Public Health, Ghent University, the National Institute on Drug Abuse, the UMass Division of Medical Toxicology, the American College of Medical Toxicology (ACMT), and the National Drug Early Warning System (NDEWS), among many others. In addition, the CFSRE appreciates its technical collaborative partners: Cayman Chemical, SCIEX, and Waters Corporation.
